Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Vaccination and infection prevention in later life
Medicine of older adults · UK scope · Sources checked 27 Aug 2026 · Clinical review pending
!
Severe vaccine reaction or outbreak illness
Anaphylaxis after vaccination, severe respiratory or sepsis physiology, meningococcal features, rapidly spreading shingles in immunosuppression or a care-home outbreak with vulnerable residents requires immediate clinical and public-health action.
Action: Use ABCDE and intramuscular adrenaline for anaphylaxis under the emergency protocol, treat acute infection, isolate proportionately, notify the relevant health-protection service and begin source-specific outbreak control without waiting for every test result.
Role and principles
Use the current UK immunisation programme and layered infection-prevention measures to reduce serious respiratory, shingles, pneumococcal and care-associated disease while adapting consent, timing, contraindications and delivery for frailty and care settings.
Use the current national schedule rather than memory. Review GP, community pharmacy, occupational health and care-home records and ask vaccines received elsewhere. Identify age cohort, splenic dysfunction, immune suppression, chronic heart, lung, kidney, liver or neurological disease, diabetes, residential setting, travel and exposure risks. A missing record should prompt verification and catch-up planning rather than assuming immunity.
Influenza vaccination is offered every season to eligible older adults and clinical-risk groups because strains and immunity change. Vaccinate before circulation rises where possible, but continue later while benefit remains. Product selection can vary by age and season under UKHSA guidance. Staff vaccination, sick leave and ventilation reduce introduction and spread in care settings.
COVID-19 campaign eligibility, timing and product are set seasonally following JCVI advice and national policy. Check the live NHS or Green Book programme for the current autumn or spring cohort, dose interval after infection and immunosuppression.
Assessment and patient selection
Routine programme gap
An eligible person lacks a documented influenza, shingles, RSV, pneumococcal or seasonal COVID vaccine.
Clinical-risk eligibility
Immune suppression, asplenia or chronic organ disease creates additional vaccine indications beyond chronological age.
Expected local reaction
Short-lived pain, redness, fatigue or low fever occurs without airway, circulatory or severe systemic features.
Vaccine anaphylaxisRed flag
Rapid airway, breathing or circulation compromise after administration requires immediate intramuscular adrenaline.
Care-setting outbreakRed flag
Linked respiratory or gastrointestinal illness affects residents or staff over a compatible period.
High-consequence infectionRed flag
Sepsis physiology, eye shingles, meningism or widespread infection in immune suppression requires urgent treatment.
Red flags requiring action
Airway swelling, wheeze, hypotension or collapse after vaccination requires immediate anaphylaxis treatment and emergency transfer.
New hypoxia, confusion, hypotension or reduced urine during an outbreak requires individual sepsis and respiratory assessment.
Vesicular rash with eye involvement, widespread lesions or immunosuppression requires urgent shingles complication assessment.
Baseline assessment
01Verified immunisation recordFirst step
Why
Identify missing doses and avoid duplication.
Interpretation and limitations
Compare GP, pharmacy, care and patient-held records and resolve product, date and course completion before catch-up.
02Eligibility and immune-status assessment
Why
Choose the current programme pathway.
Interpretation and limitations
Check age cohort, chronic disease, immune suppression, asplenia, previous infection, treatment timing and live schedule.
03Allergy and adverse-event history
Why
Distinguish contraindication from expected reaction.
Interpretation and limitations
Record exact symptoms, timing, product and suspected component; specialist allergy advice is appropriate for true anaphylaxis uncertainty.
04Capacity and consent assessment
Why
Ensure lawful and genuinely person-centred vaccination decisions.
Interpretation and limitations
Support communication and use decision-specific capacity, attorney or best-interests processes rather than blanket proxy consent.
05Outbreak line list and testing
Interventions
01First-line vaccine reviewVerify, offer and completeFirst stepFirst lineAn older adult attends a routine, chronic-disease or care-setting review.+
1Check verified records against the live UK schedule and current seasonal, age and clinical-risk eligibility.
2Assess contraindications, immune status, timing and consent and explain benefits, common reactions and important warning signs.
3Administer or book eligible doses, record product and batch in all relevant systems and recall for course completion.
02Complex eligibility routeUse the current Green Book scheduleImmune suppression, asplenia, previous vaccine, treatment timing or uncertain history complicates the plan.+
1Define the exact condition, immune treatment, previous products and dates and whether a live vaccine restriction exists.
2
Medicines and treatment safety
Prevents shingles and post-herpetic neuralgia in the current national age, catch-up and immunosuppressed cohorts.
Recombinant zoster vaccine (Shingrix)
Give 0.5 mL intramuscularly as a two-dose course; use a six-to-12-month interval for eligible immunocompetent adults and an eight-week-to-six-month interval for eligible immunosuppressed adults under the current Green Book schedule.
Confirm current eligibility and previous doses; defer significant acute febrile illness, manage bleeding risk for IM injection and use specialist advice after true component anaphylaxis.
Reduces severe respiratory syncytial virus lower-respiratory disease and hospitalisation in eligible older adults.
Adult RSV vaccine in the national programme
Give one 0.5 mL intramuscular dose to adults in the current routine-age or catch-up cohort, following the current Green Book product and coadministration guidance.
Verify live cohort and prior receipt because this is not currently an annual programme; use standard anaphylaxis preparedness and assess acute febrile illness and component allergy.
Targets, monitoring and follow-up
Record vaccine product, batch, expiry, dose, route, site, date, consent and vaccinator in interoperable records.
Use recall systems to complete two-dose courses and later seasonal campaigns rather than relying on memory.
Review expected reactions and provide instructions for airway, severe rash, neurological or prolonged systemic symptoms.
Report suspected serious adverse reactions through current Yellow Card and local clinical governance processes.
Audit coverage by age and clinical-risk cohort and investigate access gaps related to housebound status or capacity support.
During outbreaks, update line lists, tests, hospitalisations, deaths, staffing and health-protection instructions daily as required.
After an outbreak, review vaccination, ventilation, PPE, cleaning, devices, antimicrobial use and functional harms from restrictions.
Special situations
The schedule is a live source
Seasonal cohorts and programme products change, so copied eligibility tables become unsafe faster than general principles.
Shingrix is non-live
Its use in immunosuppressed cohorts differs from historical live-zoster vaccine assumptions.
Mild illness rarely blocks vaccination
Unnecessary deferral loses opportunities, whereas significant acute febrile illness merits an active rebooking plan.
One record is rarely complete
Pharmacy, GP, specialist and care-home administration need reconciliation to prevent missed or duplicate courses.
Isolation also has adverse effects
Infection control should preserve safe movement, eating, communication and cognition whenever possible.
Common pitfalls
01
Using last year's seasonal COVID eligibility without checking the current campaign.
02
Assuming no record means a vaccine was definitely never administered.
03
Treating local soreness as anaphylaxis or family allergy as a contraindication.
04
Restarting a delayed multi-dose course unnecessarily instead of following Green Book advice.
05
Assuming shingles vaccination is live and therefore always contraindicated in immunosuppression.
06
Giving repeated tetanus boosters without reviewing primary course and exposure indication.
07
Focusing on vaccination while neglecting ventilation, hand hygiene and device care.
08
Using prolonged blanket isolation without review of clinical and functional harms.
Practice
Two practice questions
Your practice draft is saved in this browser.
Question 1 of 2
0 correct
Medicine of older adultsOriginal SBA
Shingles vaccination during immunosuppression
A 72-year-old receiving immunosuppressive treatment is eligible for shingles vaccination but worries that every shingles vaccine is live. What is the best response?
Sources and review status7 sources · checked 27 Aug 2026 · clinical review pending+
Sources
Sources and review status
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.
UKHSA Green Book collectionCurrent national vaccine eligibility, products, contraindications and administration.
Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem ·
Do not
copy an age threshold from a prior year into a care plan.
RSV vaccination protects older adults from severe lower-respiratory disease. England's programme uses a single adult dose at the routine eligibility age with a catch-up cohort defined in the current schedule; it is not an annual vaccine at present. Verify timing around other vaccines and use current Green Book advice for immune suppression and bleeding risk.
Shingles vaccination uses recombinant Shingrix in the national programme. Eligible immunocompetent adults receive two intramuscular doses, generally six to 12 months apart, while eligible immunosuppressed adults use a shorter interval, generally eight weeks to six months. Confirm exact age or catch-up eligibility in the current schedule and complete the second dose rather than restarting after delay.
Pneumococcal vaccination is offered to older and specified clinical-risk groups. Check the current Green Book chapter for product, sequence and revaccination because national programmes can transition between polysaccharide and conjugate products. Splenic dysfunction, immune suppression, cochlear implant and CSF leak have additional schedules that need specialist or Green Book confirmation.
Review other protection: tetanus, diphtheria and polio primary completion and wound boosters; pertussis exposure; hepatitis A or B, meningococcal and travel vaccines according to risk; and household or occupational vaccination where it protects a vulnerable person. Do not give repeated tetanus boosters without checking the primary course and exposure indication.
Screen contraindications accurately. A previous anaphylactic reaction to a vaccine or component needs specialist advice; local soreness, fever or family allergy is not the same. Inactivated vaccines cannot cause the target infection and are generally usable in immunosuppression, though response may be reduced. Live vaccines require immune-status and product-specific assessment; Shingrix is non-live.
Obtain valid consent. Explain expected benefit, common reactions, important rare harms, alternatives and the disease risk in an accessible format. Assess decision-specific capacity and involve a relevant attorney or best-interests process when capacity is absent. Do not use a blanket care-home consent; record the product, batch, expiry, site, route, date and vaccinator and communicate to the GP record.
Plan delivery around frailty. Use seated observation and falls-safe clothing, appropriate needle and bleeding-risk technique, and monitor according to local protocol. Have anaphylaxis equipment and trained staff immediately available. Fever, pain or fatigue can worsen delirium transiently; provide hydration, analgesia advice and clear escalation without presenting routine reactions as infection.
Infection prevention remains layered because vaccines are incomplete. Support hand hygiene, respiratory etiquette, adequate ventilation, cleaning of shared equipment, mouth and skin care, catheter and line review and PPE based on organism and exposure. Antimicrobial stewardship prevents Clostridioides difficile and resistance. Preserve movement, meals and relationships during precautions where possible.
For suspected outbreak, define syndrome and onset, begin a line list, isolate or cohort proportionately, obtain testing and contact the local health-protection team under current arrangements. Apply organism-specific exclusion, treatment or prophylaxis advice. Continue individual clinical assessment because a resident can deteriorate despite being one case in a cluster. Afterward, review vaccination, ventilation, staffing, supplies and lessons.
Key points
Check the live UK routine schedule and Green Book at every review because age cohorts, products and seasonal eligibility can change.
Offer annual influenza vaccination to current eligible older adults and risk groups before the main season, without missing later opportunities.
COVID-19 vaccination follows the current seasonal JCVI and national campaign; do not assume last year's age threshold or product.
The adult RSV programme offers a single dose at the routine age and current catch-up cohort, with eligibility confirmed from the live schedule.
Shingrix is a non-live two-dose shingles vaccine used in the current age and immunosuppressed cohorts, with interval determined by immune status.
Offer the current national pneumococcal vaccine to eligible age and clinical-risk groups and verify prior doses, as programme product can change.
First-line vaccine assessment checks records, age and risk eligibility, immune suppression, pregnancy where relevant, allergy phenotype, acute illness and consent.
Mild illness is not usually a reason to defer; defer significant acute febrile illness when appropriate and rebook with named follow-through.
Infection prevention layers vaccination with hand and respiratory hygiene, ventilation, cleaning, device care, PPE by risk and antimicrobial stewardship.
Fever and rapidly progressive non-blanching rash or meningism requires emergency meningococcal treatment and notification.
Multiple linked respiratory or diarrhoeal cases in a care setting requires prompt outbreak reporting and coordinated control.
A previous true anaphylactic reaction to a vaccine component requires specialist assessment rather than routine administration or blanket avoidance.
Why
Define spread and guide control.
Interpretation and limitations
Record person, onset, symptoms, location, tests, vaccination, outcome and staff links under health-protection advice.
06Individual deterioration assessment
Why
Detect severe disease within a cluster.
Interpretation and limitations
Use ABCDE, glucose, observations and source-specific examination; outbreak status never replaces sepsis or respiratory assessment.
07Environment and device audit
Why
Identify modifiable environmental and care-associated transmission routes.
Interpretation and limitations
Review ventilation, hand facilities, cleaning, shared equipment, PPE, catheter or line care, staffing and isolation feasibility.
Use the current disease-specific Green Book chapter and seek immunisation specialist advice rather than guessing intervals.
3Create a dated course and follow-up plan across GP, pharmacy, specialty and care-home records.
03Anaphylaxis routeTreat immediately and document preciselyAirway, breathing or circulation features develop after vaccination.+
1Call for help, lay appropriately, give intramuscular adrenaline under the anaphylaxis protocol and repeat according to response.
2Provide airway, oxygen, fluids and emergency transfer and observe or investigate according to severity and treatment.
3Document product, batch, timing and phenotype and report and refer under current pharmacovigilance and allergy processes.
04Outbreak-control routeProtect residents without abandoning functionLinked respiratory, diarrhoeal or other infectious cases occur in a shared setting.+
1Start case definition, line list, testing, proportionate isolation, PPE, cleaning and health-protection notification promptly.
2Assess each resident clinically and use organism-specific treatment, prophylaxis, exclusion and vaccination advice.
3Maintain hydration, nutrition, movement and communication and review ventilation, staffing and lessons when transmission ends.
Care-home outbreak plans require early recognition, line listing, testing, health-protection advice, staffing and proportionate isolation that preserves nutrition, movement and communication.